Published in final edited form as:

Transl Stroke Res. 2013 June ; 4(3): 375–378. doi:10.1007/s12975-012-0231-4.

Polymorphisms in *ACVRL1* and *Endoglin* genes are not associated with sporadic and HHT related brain AVMs in Dutch patients

Kim Boshuisen, MD^{#1}, Manon Brundel, MD^{#1}, Carolien G.F. de Kovel, PhD², Tom G. Letteboer, MD², Gabriel J.E. Rinkel, MD¹, Cornelis J.J. Westermann, MD³, Helen Kim, PhD⁴, Ludmila Pawlikowska, PhD⁴, Bobby P.C. Koeleman, PhD², and Catharina J.M. Klijn, MD¹

¹Department of Neurology and Neurosurgery, Rudolf Magnus Institute of Neurosciences, University Medical Center Utrecht, Heidelberglaan 100, 3484CX, The Netherlands ²Department of Biomedical Genetics and Complex Genetics, University Medical Center Utrecht, Heidelberglaan 100, 3484CX, The Netherlands ³Department of Pulmonology, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands ⁴Department of Anesthesia and Perioperative Care and Department of Epidemiology and Biostatistics, University of California, San Francisco, 500 Parnassus Avenue, San Francisco, CA 94143-0244, USA

These authors contributed equally to this work.

Abstract

We aimed to replicate the association of the IVS3-35A>G polymorphism in the activin receptor-like kinase (*ACVRL1*) gene and the 207G>A polymorphism in the endoglin (*ENG*) gene with sporadic brain arteriovenous malformations (BAVM) in Dutch BAVM patients. In addition, we assessed whether these polymorphisms contribute to the risk of BAVM in patients with hereditary haemorrhagic telangiectasia type 1 (HHT1). We genotyped 143 Dutch sporadic BAVM patients and 360 healthy volunteers for four variants in the *ACVRL1* gene including IVS3-35A>G and two variants in the *ENG* gene including 207G>A. Differences in allele and genotype frequencies between sporadic BAVM patients and controls and their combined effect were analysed with a likelihood ratio test. Furthermore, we compared the allele and genotype frequencies between 24 HHT1 patients with a BAVM with those of a relative with HHT1 without a BAVM in a matched pair analysis using Wilcoxon signed rank test. No significant differences in allele frequency were found between sporadic BAVM cases and controls or between HHT1 patients with and without BAVM for any of the polymorphisms or the combination of *ACVRL1* and *ENG* polymorphisms. Meta-analysis of the current and the two previous studies for the *ACVRL1* IVS3-35A polymorphism showed a persisting association between the *ACVRL1* IVS3-35A polymorphism and risk of sporadic BAVM (OR 1.86; 95% CI 1.32–2.61, $p < 0.001$). We did not replicate the previously found association between a polymorphism in *ACVRL1* IVS3-35A>G and BAVM in Dutch patients. However, meta-analysis did not rule out a possible effect.

Corresponding author: Manon Brundel, University Medical Center Utrecht, Department of Neurology G03.232, P.O. Box 85500, Heidelberglaan 100, 3508 GA Utrecht, The Netherlands Phone: +31 88 7558258, Fax: +31 30 2542100, M.Brundel-2@umcutrecht.nl.

Competing interests None

Keywords

Arteriovenous malformations; Etiology; Genetics; Neurogenetics; Cerebrovascular disease

Introduction

There is increasing evidence for a genetic component in the etiology of brain arteriovenous malformations (BAVM) from candidate gene studies, genome wide expression studies of BAVM tissue and, most recently, gene expression profiling of blood in BAVM patients [1–3]. Familial clustering of supposedly 'sporadic' BAVMs has been described [4]. Furthermore, the prevalence of BAVMs is increased in patients with the autosomal dominant disorder hereditary haemorrhagic telangiectasia (HHT) [5–7]. Mutations in the endoglin (*ENG*) gene lead to HHT1 and mutations in the activin receptor-like kinase 1 (*ACVRL1*) gene to HHT2. BAVMs occur in 9–21% of HHT1 patients, yet rarely in patients with HHT2, indicating that mutations in *ENG* may be involved in the occurrence of BAVMs [8]. Both *ENG* and *ACVRL1* play a role in the transforming growth factor- β (TGF- β) signalling pathway involved in angiogenesis, vascular remodelling and regulation of endothelial cell function [9]. Previously, an association between the *ACVRL1* IVS3-35A>G polymorphism and sporadic BAVM has been reported in an American population of 177 Caucasian patients with sporadic BAVM and 129 controls (OR 2.47, 95% CI 1.38–4.44; p-value 0.002) and in a German study on 94 BAVM patients and 202 controls (OR 2.35, 1.16–4.76; p-value 0.018; analysis any A versus GG) as well as a possible modifying role of *ENG* 207G>A [10,11].

We aimed to replicate the association of *ACVRL1* IVS3-35A>G with sporadic BAVMs and the modifying effect of *ENG* 207G>A in a series of Dutch patients with sporadic BAVM and patients with HHT1. In addition, we genotyped additional tagging single nucleotide polymorphisms (SNPs) in both genes to test whether other common polymorphisms might exist in *ACVRL1* or *ENG* that contribute to the risk of a BAVM in sporadic and HHT1 patients.

Patients and Methods

The study was approved by the institutional ethical committee of the University Medical Center Utrecht (UMCU).

Sporadic BAVM Patients and Controls

The study cohort consisted of 143 non-related Dutch patients with sporadic BAVM (55% male, mean age 47 $\pm$ 13 years, 61 (42.7%) presenting with haemorrhage), referred to the UMCU between 1991 and 2005. The control group consisted of 360 Dutch healthy blood bank volunteers. Participants were considered to be of Dutch descent if all grandparents were born in the Netherlands.

HHT Patients

Between 1982 and 2008, 281 genetically confirmed HHT patients (210 HHT1; 71 HHT2) of 95 families of Dutch descent were referred to the St. Antonius Hospital Nieuwegein. Thirty-three HHT1 patients and none of the HHT2 patients had a BAVM. In four families more than one member had a BAVM.

Of the 33 HHT1 patients with a BAVM, patients with available DNA were included (n=24, 46% male, mean age 45±15 years). Each patient with a BAVM was matched with a relative with HHT1 without a BAVM (54% male, mean age 45±15 years). Furthermore, BAVM-negative patients of BAVM-positive families were compared to BAVM-negative patients of BAVM-negative families (n=41).

Genotyping

For *ACVRL1* we genotyped the variant IVS3-35A>G (rs2071219)[10,11] and three additional SNPs (rs3759178, rs11169953, rs706819), which tagged all known variants with minor allele frequency 5% and $r^2 > 0.8$ as calculated with Haploview software, using the Hapmap CEU database. For *ENG*, we genotyped 207G>A (rs16930129)(10) and -1742A>G (rs10987759). Genotyping was performed with Taqman assays for ABI 7900 HT Fast Real Time PCR system (Applied Biosystems, Foster City, Ca) according to the specifications of the manufacturer.

Statistical Analysis

All SNPs were tested for deviation from Hardy Weinberg expectations by χ^2 goodness of fit test (threshold $\alpha=0.008$, equivalent to $\alpha=0.05$ after Bonferroni correction for six SNPs). We analysed differences in allele and genotype frequencies between sporadic BAVM patients and controls with a likelihood ratio test (UNPHASED v3.0).[12] We studied the combined effect of the genotypes of *ACVRL1* IVS-35G>A (rs2071219) and *ENG* 207G>A (rs16930129) by a two locus allelic combination analysis in UNPHASED. We combined our results with those of the two published studies and assessed possible heterogeneity of the odds ratio (OR) using the Mantel-Haenszel chi-square test.

For the analysis between HHT1 BAVM-positive and BAVM-negative patients within families, we coded genotypes as 0, 1 or 2 minor alleles using a Wilcoxon Signed Rank test.

Results

All polymorphisms were in Hardy-Weinberg equilibrium. We did not find significant differences between patients with sporadic BAVM and controls for any of the SNPs (Table 1).

Furthermore, for the combination of *ENG* 207G>A and *ACVRL1* IVS3-35A alleles, we did not find significant ORs for any allele combination (G-A [55% of BAVM patients, 53% of controls], OR 0.96 95% CI 0.44–2.11; G-G [37% of BAVM patients, 38% of controls], OR 0.91, 95% CI 0.40–2.11; A-A [3% of BAVM patients, 5% of controls], OR 0.59, 95% CI 0.15–2.34 compared to A-G [5% of BAVM patients, 4% of controls] as reference).

However, meta-analysis of the current results and the two previous studies for the *ACVRL1* IVS3-35A polymorphism showed a persisting association between the *ACVRL1* IVS3-35A polymorphism and risk of sporadic BAVM (OR 1.86; 95% CI 1.32–2.61, $p < 0.001$; any A versus GG). We did not find evidence for OR heterogeneity among our study and the two previous studies (p -value 0.203). In HHT1 patients, we did not find significant differences in the number of minor alleles at *ACVRL1* between patients with and without a BAVM or between patients of BAVM-positive and BAVM-negative families (Table 2). We observed a trend for association with the *ENG* 207 polymorphism in BAVM-positive families versus BAVM-negative families (p -value 0.056). Genotyping of the rs706819 SNP was technically insufficient to draw any conclusions from.

Discussion

In this study of Dutch sporadic BAVM patients we did not replicate the previously reported association with *ACVRL1* or *ENG* polymorphisms [10,11]. The *ACVRL1* IVS3-35A allele was also not associated with presence of a BAVM in HHT1 patients.

The discrepancy with associations found in the two previous studies could be due to population differences, although all cohorts that were studied consisted of Caucasian patients and demographic characteristics were similar. The proportion of patients who had presented with haemorrhage was slightly lower (42,7%) in our Dutch cohort than that in the American patients (63.8%). [10] The frequency of *ACVRL1* IVS3-35A in our control group was slightly higher than in the control groups of the two previously published studies, but we found no heterogeneity in the observed ORs. Despite the reasonable power (~80%), it is possible that our results are false negative, caused by an overestimate of the effect size in the initial report due to the 'winners curse' [13]. We also found no support for the hypothesis that other common polymorphisms in the *ACVRL1* gene contribute to the risk of a BAVM in HHT1 patients, and only weak trends toward association for polymorphisms in the *ENG* gene were found. However, the power of this analysis was limited given the relatively small sample size. Taken together, our results suggest that the pathophysiology of both sporadic and familial BAVMs is complex and other genes or environmental factors might play an important role in the development of BAVMs.

Further studies to find genetic determinants of development and behaviour of BAVMs are needed and should include large numbers of patients. For a disease as rare as BAVM, studies of large cohorts can only be accomplished through international collaboration.

Acknowledgments

None

Funding This study was supported in part by grants from the National Institutes of Health: R01 NS034949 and P01 NS044155.

References

1. Young WL, Yang GY. Are there genetic influences on sporadic brain arteriovenous malformations? *Stroke*. 2004; 35:2740–5. [PubMed: 15472089]

2. Kim H, Su H, Weinsheimer S, Pawlikowska L, Young WL. Brain arteriovenous malformation pathogenesis: a response-to-injury paradigm. *Acta Neurochir Suppl.* 2011; 111:83–92. [PubMed: 21725736]
3. Weinsheimer SM, Xu H, Achrol AS, Stamova B, McCulloch CE, Pawlikowska L, Tian Y, Ko NU, Lawton MT, Steinberg GK, Chang SD, Jickling G, Ander BP, Kim H, Sharp FR, Young WL. Gene expression profiling of blood in brain arteriovenous malformation patients. *Transl Stroke Res.* 2011; 2:575–87. [PubMed: 22184505]
4. van Beijnum J, Van der Worp HB, Schippers HM, van Nieuwenhuizen O, Kappelle LJ, Rinkel GJ, Berkelbach van der Sprenkel JW, Klijn CJ. Familial occurrence of brain arteriovenous malformations: a systematic review. *J Neurol Neurosurg Psychiatry.* 2007; 78:1213–7. [PubMed: 17259353]
5. Letteboer TG, Mager JJ, Snijder RJ, Koeleman BP, Lindhout D, Ploos van Amstel JK, Westermann CJ. Genotype-phenotype relationship in hereditary haemorrhagic telangiectasia. *J Med Genet.* 2006; 43:371–7. [PubMed: 16155196]
6. Sabba C, Pasculli G, Lenato GM, Suppressa P, Lastella P, Memeo M, Dicuonzo F, Guant G. Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers. *J Thromb Haemost.* 2007; 5:1149–57. [PubMed: 17388964]
7. Bayrak-Toydemir P, McDonald J, Markewitz B, Lewin S, Miller F, Chou LS, Gedge F, Tang W, Coon H, Mao R. Genotype-phenotype correlation in hereditary hemorrhagic telangiectasia: mutations and manifestations. *Am J Med Genet A.* 2006; 140:463–70. [PubMed: 16470787]
8. Lesca G, Olivieri C, Burnichon N, Pagella F, Carette MF, Gilbert-Dussardier B, Goizet C, Roume J, Rabilloud M, Saurin JC, Cottin V, Honnorat J, Coulet F, Giraud S, Calender A, Danesino C, Buscarini E, Plauchu H, French-Italian-Rendu-Osler Network. Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network. *Genet Med.* 2007; 9:14–22. [PubMed: 17224686]
9. Abdalla SA, Letarte M. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. *J Med Genet.* 2006; 43:97–110. [PubMed: 15879500]
10. Pawlikowska L, Tran MN, Achrol AS, Ha C, Burchard E, Choudhry S, Zaroff J, Lawton MT, Castro R, McCulloch CE, Marchuk D, Kwok PY, Young WL, UCSF BAVM Study Project. Polymorphisms in transforming growth factor-beta-related genes ALK1 and ENG are associated with sporadic brain arteriovenous malformations. *Stroke.* 2005; 36:2278–80. [PubMed: 16179574]
11. Simon M, Franke D, Ludwig M, Aliashkevich AF, Koster G, Oldenburg J, Bostrom A, Ziegler A, Schram J. Association of a polymorphism of the ACVRL1 gene with sporadic arteriovenous malformations of the central nervous system. *J Neurosurg.* 2006; 104:945–9. [PubMed: 16776339]
12. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. *Genet Epidemiol.* 2003; 25:115–21. [PubMed: 12916020]
13. Ioannidis JP. Why most discovered true associations are inflated. *Epidemiology.* 2008; 19:640–8. [PubMed: 18633328]

Table 1

Genotype and allele frequencies of polymorphisms in *ACVR1L1* and *ENG* in patients with sporadic BAVM and controls

Genotype	Sporadic BAVM patients n (%)	Controls n (%)	OR (95% CI)*	allele frequency	Sporadic BAVM patients n (%)	Controls n (%)	OR (95% CI)*
<i>ENG207G>A</i> (rs16930129)							
G/G	118(84.9)	298(83.2)	1.06(0.61–1.82)	G	257(92.5)	652(91.1)	1.20(0.72–2.01)
G/A	21(15.1)	56(15.6)	1	A	21(7.6)	64(8.9)	1
A/A	0(0)	4(1.1)	-				
<i>ENG-1742A>G</i> (rs10987759)							
A/A	0(0)	4(1.1)	-	A	20(7.2)	58(8.2)	0.86(0.51–1.47)
A/G	20(14.3)	50(14.1)	1.00(0.57–1.76)	G	260(92.9)	652(91.8)	1
G/G	120(85.7)	301(84.8)	1				
<i>rs3759178</i>							
G/G	25(17.7)	54(15.3)	1.05(0.60–1.84)	G	105(37.2)	269(38.1)	0.96(0.72–1.28)
G/T	55(39.0)	161(45.6)	0.77(0.50–1.19)	T	437(62.8)	437(61.9)	1
T/T	61(43.3)	138(39.1)	1				
<i>rs11169953</i>							
C/C	65(46.8)	163(46.2)	1.35(0.68–2.67)	C	191(68.7)	472(66.9)	1.09(0.81–1.47)
C/T	61(43.9)	146(41.4)	1.41(0.71–2.81)	T	87(31.3)	234(33.1)	1
T/T	13(9.4)	44(12.5)	1				
<i>ACVR1L1 IVS3-35A>G</i> (rs2071219)							
A/A	44(31.7)	123(34.8)	1.12(0.62–2.02)	A	161(57.9)	407(57.7)	1.01(0.76–1.34)
A/G	73 (52.5)	161(45.6)	1.42(0.82–2.47)	G	117(42.1)	299(42.4)	1
G/G	22(15.8)	69(19.6)	1				
<i>rs706819</i>							
C/C	71(52.2)	194(55.8)	0.70(0.33–1.48)	C	195(71.7)	519(74.6)	0.86(0.63–1.18)
C/T	53(39.0)	131(37.6)	0.77(0.36–1.67)	T	77(28.3)	177(25.4)	1
T/T	12(8.8)	23(6.6)	1				

* Pearson chi-square, expected values were at least >5 in 90% of the cells

Table 2

Allele frequencies in BAVM-positive and BAVM-negative HHT patients

	BAVM (+)			BAVM(-) in BAVM(+) families			BAVM(-) in BAVM(-) families		
	allele frequency	no. patients		allele frequency	no. patients		allele frequency	no. patients	p-value [†]
ENG-1742A>G	0.11	22		0.09	22		0.02	41	0.095
ENG207 G>A	0.19	24		0.15	24		0.06	41	0.056
rs3759178	0.42	19		0.35	19		0.40	41	0.527
rs11169953	0.37	19		0.35	19		0.30	41	0.683
ACVRL1 IVS3 35A>G	0.57	15		0.60	15		0.59	41	0.849

* Wilcoxon Signed Rank test: Comparison of BA VM-positive HHT1 patients with their BAVM-negative relatives
[†] Pearson Chi square test: Comparison of BAVM-negative patients of BAVM-positive HHT1 families versus BAVM-negative patients of HHT1 BAVM-negative families.